04-02-2025
Saudi summit: GLP-1 drugs could revolutionize global health, access remains a challenge
A leading obesity researcher has called for broader access to revolutionary GLP-1 weight-loss drugs such as Ozempic and Wegovy at Saudi Arabia's Global HealthSpan Summit, which is highlighting the importance of longer, healthier lives.
Speaking at the second annual Global HealthSpan Summit, organized by the Kingdom's Hevolution Foundation, David Bradley Allison raised crucial questions about the future of GLP-1 drugs, which have shown remarkable effectiveness in treating obesity and potentially extending healthy lifespans.
'Who decides who gets these drugs? Who pays for them?' Allison asked, addressing the ethical considerations surrounding access to these medications. 'Should a person be able to choose to take one of these drugs for their benefits that they perceive, even if it's not judged by mainstream medicine as medically indicated?' Allison questioned, highlighting the tension between personal choice and medical oversight.
Addressing concerns about the high cost of GLP-1 drugs, Allison drew parallels with other technologies that became more affordable over time.
'People talk about how it would cripple the economy, but these are predicated on assumptions that the price doesn't come down,' he said. 'Pocket calculators were very expensive in 1970. Now you give pocket calculators away.'
The researcher also noted ongoing developments in drug delivery systems, including oral medications currently in development as alternatives to injections, which could potentially increase accessibility and reduce costs.
While acknowledging the promise of GLP-1 drugs, Allison emphasized the importance of addressing broader social and economic factors affecting public health. He cited two significant studies demonstrating the impact of environmental and educational factors on obesity rates.
The Moving to Opportunity study, a long-term randomized controlled trial by the US Department of Housing and Urban Development, showed that people who moved to better housing conditions were less likely to develop obesity and diabetes decades later.
Similarly, the Abecedarian study revealed that early intervention programs focusing on education and parent training led to lower obesity rates, particularly among women and girls.
When asked about potential policy solutions, Allison advocated for a freedom-oriented approach rather than restrictions.
'I like giving things, not taking things,' he said, suggesting that government action should focus on making anti-obesity medications more accessible while ensuring proper informed consent.
The summit was organized by the Hevolution Foundation, established by Saudi Crown Prince Mohammed bin Salman through a royal decree. The foundation commits over one billion dollars annually to research aimed at extending healthy human lifespans, representing one of the largest investments in longevity science globally.
The non-profit foundation aims to democratize access to healthspan science to benefit all of humanity, marking a significant shift in Saudi Arabia's role in global health research.
The discussion comes at a time when GLP-1 drugs have gained significant attention for their effectiveness in treating obesity and potential implications for healthy aging.
These medications work by mimicking hormones that influence appetite, fullness, and digestion, representing a potentially transformative approach to treating obesity and related conditions.
